Ascentage Pharma presents data for Lisaftoclax at 2025 ASH

Ascentage Pharma (AAPG) Group International announced that it has presented an oral report featuring the latest results from a registrational Phase II study conducted in China of Lisaftoclax, a key drug candidate in the Company’s pipeline, as a monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who had failed Bruton’s tyrosine kinase inhibitors, at the 67th American Society of Hematology, ASH, Annual Meeting, being held in Orlando, FL. Data from this pivotal trial supported the NDA approval that was granted to Lisaftoclax by China’s National Medical Products Administration in July 2025. Key highlights: Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new treatment option; Lisaftoclax achieved a 62.5% objective response rate in heavily pretreated, BTKi-refractory patients, nearly half with complex karyotype; Lisaftoclax monotherapy demonstrated a median progression-free survival of 23.89 months in patients with heavily pretreated BTK-refractory R/R CLL/SLL, with no tumor lysis syndrome reported